Endra Life Sciences Inc (NDRA)

[dndodd]

Maybe but folks on the new drugs that are coming will need to measure the progress as will the Dr's. A radiologist I know who see's more and more Fatty Liver weekly then he was seeing 5-10 years ago thinks this is a great tool.

You sound like me and Zoom I didn't see the need should have invested.

[biotech_researcher]

Ultrasound told us it was minimal, so a regular ultrasound machine can determine if one’s fatty liver needs further tests.

[dndodd]

They can't quantify mildly fatty can they?

Check out the new presentation especially at the end where it compares the various options.

https://s3.amazonaws.com/cdn.irdirect.net/PIR/957/4797/ENDRA%20Life%20Sciences%20Investor%20Presentation%20Sept%202020%20Final%20V2.pdf

Is her liver over 5 or 25%? If it was my liver I would want to know?

Endra TAEUS can tell you normal Ultrasound cannot.

[dndodd]

Not sure, I know. He has a good relationship with one of the other board members who is also a large shareholder.

[derkampfer]

Why is Lou B on the Board? That makes no sense. What value does someone like him add?? First Clearsign, then leaves. Now Endra.

[biotech_researcher]

“
Endra looks very promising, but they need to publish more data and should test in combination with standard non invasive markers, such as blood tests, BMI ect ect, as these are done anyway at the PCP.
All adds up to a better Sensitivity / specificity.”

This is key and Endra doesn’t want to share comparative results.

As I’ve mentioned my wife had an ultrasound on her liver and the medical report indicated a mildly fatty liver with no further tests required.

What additional specificity is provided by Endra’s device?

[Tonyboons33]

Great info and read on it, thank you!

[Tonyboons33]

I always value your opinion, so much appreciated!!

[Sluicebox]

I think very few knows about Endra.
The point many misses is that gold standard is achieved by a very expensive MRI scanning, and is really not part of standard of care in the early lines of NAFLD, which is where the big market opportunity is for Endra. To diagnose and start treatment of NAFLD in the early stage.

I think the implementation of TAEUS, based on current data, is to replace biopsy, fribroscan and ultrasound at specialist after their Primary Care Physician has established suspicion of NAFLD.

Fact that current major share holders want to buy more shares is great. They paid about .84. Had it been a public offering they would have had to give 15-20% discount on sp anyway, so we might be better of this way.

Endra looks very promising, but they need to publish more data and should test in combination with standard non invasive markers, such as blood tests, BMI ect ect, as these are done anyway at the PCP.
All adds up to a better Sensitivity / specificity.

[dndodd]

I know you didn’t ask me but thought I would add my .02.

I don’t think the Market really knows about TAEUS yet that will come with sales and FDA approvals.

The warrants exercised at .70 but they paid approximately.14 for each warrant for a total cost .84 to the investor.

The insiders exercised their warrants a couple of weeks earlier at full price of .87 plus the .14 they paid. Bullish IMO.

[Tonyboons33]

Do you think the market is not impressed with these figures and they're not "gold standard" enough to be a disrupter? Also, thoughts on the recent exercise of warrants generating $5 mill for the company? Said that ENDRA "accepted reduced exercise prices".

[Sluicebox]

Interesting video. TAEUS reached AUROC .91 and 0.88 at MRI-PDFF values of 6% and 15%, respectively. So not quite up to gold standard above 6%. So guess TAEUS can be used in the early stages of the disease only as the gold standard of non invasive markers and just rival other non invasive markers >6% but below gold standard. The number here comes from NDRAs own Clinical Feasibility Study on their website. At least this is how I understand the numbers and the essence the video.

[biotech_researcher]

A nothing Burger..

[dndodd]

During the COVID-19 pandemic, it is important to increase diagnostics for liver disease because a growing number of studies have found that fatty liver increases the risk for severe COVID-19 symptoms. Healio Gastroenterology spoke with Francois Michelon, CEO of ENDRA Life Sciences,


https://www.healio.com/news/hepatology/20200811/qa-new-tool-may-detect-liver-fat-early-on-to-prevent-nash-nafld

[iKnow777]

What’s the cost of making that kit?

[dndodd]

Not a bid deal just needs to go above a dollar for 10 days.

Spoke with IR won’t be a concern if that doesn’t happen by next year.

[Tonyboons33]

Any thoughts on the below disclaimer on my TD Brokerage account? Is this b/c of time they've spent below $1? Anyway for us to confirm if it's that or some other listing requirement?

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

[dndodd]

a new white paper providing a comprehensive review of the NAFLD-NASH diagnostic technology landscape.


It is posted on ENDRA's website (https://endrainc.com/research-and-media) and we believe it will be of interest to investors, clinicians and potential strategic partners.

[dndodd]

Noninvasive Assessment of NAFLD/NASH

[dndodd]

I think everyone realizes the pieces are in place and we are waiting.

Europe progress(made difficult by the virus but still in progress), FDA approval, the first P.O., and operating funds are all things in process we are waiting for to occur. Probably some things we don't know that will be positive surprises.

Funding will not be an issue, see the latest SEC filings.


Insider buying is great.

[Tonyboons33]

It's hanging on nicely around $1 and where'd all the chatter go?????

[dndodd]

ENDRA Life Sciences Granted Additional European Patent As Commercialization Begins

New grant expands coverage of key U.S. platform patent to Europe

ANN ARBOR, MI / ACCESSWIRE / July 22, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued European Patent 3328285 from the European Patent Office (EPO).

"The granting of our second European patent comes at an opportune time, as we're currently focusing on finalizing our first clinical evaluation reference sites in Europe and initiating sales in this key market, where the TAEUS Fatty Liver Imaging Probe System received CE Mark Approval in the first half of the year," said ENDRA's Chief Executive Officer, Francois Michelon.

Kai Thomenius PhD, a research scientist at the Institute of Medical Engineering & Science at The Massachusetts Institute of Technology (MIT) and co-inventor of the patent, said, "This is a novel approach to correcting fat induced image distortion in ultrasound imaging, leveraging the inherent fat and lean tissue contrast of thermoacoustics."

"While our European patent grants are significant because they apply to our platform capabilities in our first commercial market, it is important to understand these patents are supported and strengthened by the fact they are part of a growing IP portfolio, which currently stands at 72 assets, which cover other critical aspects of our technology," concluded Michelon.

[biotech_researcher]

Of course Chinese patents are priced at the same value as toilet paper in today’s market..

[dndodd]

No clue but the only thing stopping it at this point is the ask at 1.05 with about 40,000 shares.

[Tonyboons33]

Any thoughts as to what's happening today? Taking off and love to see this volume!!!

[biotech_researcher]

ENDRA Life Sciences Expands Global Technology Protection With New Chinese Patents

Grants further protect ENDRA's TAEUS® platform capabilities in key international market with over 400 million potential NAFLD patients

ANN ARBOR, MI / ACCESSWIRE / July 13, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued Chinese Patents ZL 2016 8 00267289 and ZL 2019 3 04324291 from the Chinese Intellectual Property Office.

"The granting of these patents further expands the protection of our platform technology in the key international market of China, where an estimated 29.2% of the population is affected by Non-Alcoholic Fatty Liver Disease, according to a recent study published in Hepatology," said ENDRA's Chief Executive

[biotech_researcher]

There was no interpretation by me. It was a posting from Endra’s web site..

[dndodd]

I don’t believe your interpretation.

[biotech_researcher]

It is information straight from Endra’s web site: “Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. “

Seems believable if it was posted there don’t you think?

[dndodd]

Very. I have done enough DD on my own rather then take a strangers interpretation on the internet (who I know nothing about) in regards to a very technical document.

[biotech_researcher]

Revealing that you would comment on my understanding but would not answer my question on your understanding, which was:


dndodd's comment:
"It is my understanding TAEUS is very close to being as good as an MRI in quantifying liver fat"

My comment:
dndodd, Your understanding would be incorrect.

[dndodd]

I have spoken to several experts that don’t concur with your interpretation.

[biotech_researcher]

"It is my understanding TAEUS is very close to being as good as an MRI in quantifying liver fat"

Your understanding would be incorrect.

[biotech_researcher]

Dndodd, these are facts from NDRA's filings. Many of your posts are "hopeful thoughts" and not in the realm of science. Good luck to you with this investment.

[dndodd]

What “seems” right to you is obviously not reality.

[biotech_researcher]

"Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. This explains a lot.....

[biotech_researcher]

Thank you derkamp

[dndodd]

You do not know if GE sees the value or not, pure supposition on your part.

[biotech_researcher]

dndodd, I expect you will know the true value before me. GE doesn’t see the value. This would be a rounding error on their tax return..

[dndodd]

The only persons I have come across that is qualified to answer your questions is someone from Endra or there is a poster on Stocktwits - GenomeGuru who I believe is qualified to give you a good answer.

[dndodd]

As much as I follow Endra I am not qualified to properly interpret the results of a clinical trial I rely on the investor presentation; https://s3.amazonaws.com/cdn.irdirect.net/PIR/957/4471/ENDRA%20Life%20Sciences%20Investor%20Presentation%20June%202020.pdf

It is my understanding TAEUS is very close to being as good as an MRI in quantifying liver fat which depending on who you talk to is considered the gold standard for liver fat. Other clinicians have said the liver biopsy is considered the gold standard but they may also be trying to check for fibrosis at the same time.

I found a you tube presentation on Liver Disease -The Silent epidemic By a Dr from UCSF to be very educational I believe her name is Danielle Brandman.
Beyond that reach out to Endra for answers they are generally very responsive.

[Sluicebox]

First time looking at this stick so excuse me if I got it wrong, but please explain
Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. How does that work in real life. Wouldn't we simply just continue using biopsy and be sure ?

[Marksch1]

Im holding out for .80-.81 area and then low 60's if it really gets weak, hopefully it won't come to that.

[dndodd]

Great I don’t think anybody will get hurt at these prices. I am impressed after last weeks heavy volume day the price has held up better then I expected.

[derkampfer]

Added 12,000 shares today @ $.855.

This dip is an opportunity IMHO

GLTA

[dndodd]

Also means you probably know sqaut.

The relationships are deep with GE they have first right of refusal no need for them to be in hurry.

In addition I doubt we see any type of BO offer before FDA approval and a few sales.

[Marksch1]

I don't know. I was called a brave soul and much worse for loading up cydy sub 50 cents, im now wealthier than I ever thought I would be. Not saying that's gonna happen here, but as a potential lottery ticket, I'm willing to buy some shares.

[biotech_researcher]

That means GE values their IP as squat.

[biotech_researcher]

I expect the management team is working hard and doing the best they can. The crux of the problem is that they are running out of money. GE STILL does not see the need to purchase the company and its technology for essentially chicken scratch. That bothers me immensely..

[Tonyboons33]

List of insiders purchasing is also encouraging: https://fintel.io/n/us/ndra